HAI Book 2025 - Flipbook - Page 4
29 Performance of an MR-independent
analysis pipeline for quantiocation of tau
abnormality using [18F]nortaucipir PET 169
38 Validation of PET spatial extent as
sensitive amyloid biomarker in early stages
of amyloidosis ..................................... 194
Gallego-Rudolf, Jonathan .................... 171
Frontzkowski, Lukas ........................... 197
30 Functional and structural connectivity
patterns predict longitudinal tau spreading
in asymptomatic individuals expressing A´
pathology..............................................171
39 Developing a novel reference region for
PI-2620-PET imaging to facilitate
assessment of 4-repeat tauopathies .... 197
Gatchel, Jennifer ................................ 174
31 Plasma phospho-tau 217,
neuroolament-light, and glial obrillary
acidic protein are differentially associated
with longitudinal neuropsychiatric
symptoms across the early cognitive
spectrum ............................................. 174
Gatto, Rodolfo ..................................... 178
32 An assessment of the utility of
nortaucipir PET to detect four-repeat tau
pathology in a globular glia tauopathy
case-series .......................................... 178
Clarke, Mica ......................................... 180
Arnold, Steven .................................... 199
40 P-TAU217, GFAP, and NFL plasma
biomarker associations with demographic,
medical and neurocognitive features from
middle-aged through older adulthood ... 199
Bourgeat, Pierrick .............................. 200
41 DeepSUVR: Using temporal constraints
to improve tau quantiocation .............. 200
Aumont, Etienne ................................ 204
42 Increasing the granularity of tau-PET
Braak staging using medial temporal lobe
segmentations to detect early memory
impairment......................................... 204
Povala, Guilherme .............................. 206
33 Molecular imaging of
neurodegeneration 3 mitochondria,
associated proteins and synapses (MINDMAPS) in frontotemporal dementia .......180
Garrone, Aurélie .................................. 210
34 Evaluating tVNS effects on cognitive
outcomes and modulating factors in
asymptomatic older adults: study design
of the WALLe Trial ................................ 182
44 Assessing the relationship between
neuropsychiatric symptoms, amyloid and
tau pathology, and white matter
hyperintensity volume across sexes in
preclinical Alzheimer9s disease ............. 210
Engels-Domínguez, Nina .................... 182
Dhaynaut, Maeva ................................. 186
35 Cerebral perfusion indices from earlyphase [18F]-MK6240 dynamic Tau PET
imaging in brain regions associated with
Alzheimer9s disease progression in an
aging population. ................................. 186
Baillet, Marion ..................................... 187
43 The universal tau PET scale (Uni�㔏) for
Flortaucipir, MK6240, PI2620 and RO948
harmonization .................................... 206
Diez, Ibai .............................................. 213
45 Unveiling the heterogeneity of tau
spreading in aging and Alzheimer's disease
using polygenic combinations: Towards
personalized models ............................ 213
Guzmán, Diana S.................................. 216
46 Regional amyloid and tau: Exploring
regional sex-based differences in a
middle-aged community-based cohort . 216
36 Transcutaneous auricular vagus nerve
stimulation improves learning and sleepwake quality in older APOE-ε4 carriers .. 187
Amaral, Livia ....................................... 218
37 Biological-clinical mismatch renects
co-pathology and vulnerability to
neurodegeneration ..............................190
47 Comparison of topographical patterns
of abnormalities of the tau PET tracers
[18F]Flortaucipir, [18F]MK6240,
[18F]PI2620, and [18F]RO948 ............... 218
Brown, Christopher............................. 190
Del Carmen Montenegro, Grace .......... 194
HAI2025 - 4
Felix, Cynthia ..................................... 222
